Cite
HARVARD Citation
Dytfeld, D. et al. (2023). Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet oncology. 24 (2), pp. 139-150. [Online].